<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Ten patients with <z:mp ids='MP_0002872'>polycythaemia</z:mp> vera (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>) and nine with <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythaemia</z:e> (ET) received a haemopoietic stem cell transplant (HSCT) at the Fred Hutchinson <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Research Center between May 1988 and March 2000 </plain></SENT>
<SENT sid="1" pm="."><plain>HSCT was performed because of progression to the spent phase of the disease with <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> and <z:hpo ids='HP_0001744'>splenomegaly</z:hpo> in 10 patients and evolution into a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or <z:hpo ids='HP_0011009'>acute</z:hpo> myelogenous <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) in nine patients </plain></SENT>
<SENT sid="2" pm="."><plain>Patients were 18-59 years old (median 43) </plain></SENT>
<SENT sid="3" pm="."><plain>The interval from diagnosis to HSCT was 77-300 months (median 170) </plain></SENT>
<SENT sid="4" pm="."><plain>Seven patients were splenectomized before transplantation, and <z:hpo ids='HP_0000001'>all</z:hpo> but five had been treated with cytotoxic agents </plain></SENT>
<SENT sid="5" pm="."><plain>Eleven patients received a transplant from a related, and eight from an unrelated, donor following conditioning with chemotherapy only or chemotherapy plus total body irradiation regimens </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> evaluable patients achieved sustained engraftment </plain></SENT>
<SENT sid="7" pm="."><plain>Twelve patients are surviving 5-116 months (median 41) after transplant, 10 in continued complete remission, one in haematological remission with residual marrow <z:mp ids='MP_0003045'>fibrosis</z:mp> and one with mixed haemopoietic chimaerism currently receiving therapy with interferon </plain></SENT>
<SENT sid="8" pm="."><plain>Seven patients (six with <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> and one with <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo>) died of transplant-related complications </plain></SENT>
<SENT sid="9" pm="."><plain>These data show that HSCT can provide curative therapy for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> and ET with advanced disease </plain></SENT>
</text></document>